Beta-2-Glycoprotein I Antibodies (IgG, IgA, IgM)
Beta-2-Glycoprotein I Antibody testing measures IgG, IgA, and IgM antibodies to β2GPI, a key antigen in antiphospholipid syndrome. High-titre IgG is a classification criterion for APS and correlates with arterial and venous thrombosis and pregnancy morbidity, particularly when persistent at ≥12 weeks and accompanied by lupus anticoagulant.
3
Biomarkers
Blood (plasma)
Sample
3–5 business days
Turnaround
No
Fasting
What is the β2GPI Antibodies test?
Beta-2-Glycoprotein I Antibody testing detects IgG, IgA, and IgM antibodies directed against β2GPI, a key antigenic target in antiphospholipid syndrome. Together with lupus anticoagulant and anticardiolipin antibodies, these tests form the serological arm of APS diagnosis — a condition characterised by arterial or venous thrombosis, recurrent pregnancy morbidity, or both, in the presence of persistent antiphospholipid antibodies. Practitioners order β2GPI antibodies to investigate unexplained thrombosis, recurrent miscarriage, thrombocytopenia, or livedo reticularis, and to complete the APS panel in patients with positive lupus anticoagulant or anticardiolipin results. High-titre IgG, especially when accompanied by lupus anticoagulant, carries the highest thrombotic risk, while isolated low-titre IgM or IgA results require careful interpretation and repeat testing to avoid overdiagnosis.
What does the β2GPI Antibodies test measure?
Beta-2-glycoprotein I (β2GPI, also termed apolipoprotein H) is a plasma protein that binds phospholipids and is a major antigen in antiphospholipid syndrome. IgG antibodies to β2GPI are pathogenic; they bind the protein when it is complexed with anionic phospholipid surfaces, triggering endothelial activation, increased tissue factor expression, complement activation, and dysregulated coagulation. β2GPI IgG persists longer than transient infection-associated antiphospholipid antibodies and is the most clinically significant isotype.
β2GPI IgG is one of the three core laboratory criteria for antiphospholipid syndrome, alongside lupus anticoagulant and anticardiolipin antibodies. Its presence correlates with thrombotic risk, particularly when titres are high and when accompanied by lupus anticoagulant. Isolated low-titre antibodies are less predictive and often require confirmatory testing 12 weeks later.
The IgA isotype of β2GPI antibodies is less well characterised than IgG and is not a formal classification criterion under the revised Sapporo criteria. Nevertheless, a subset of patients with clinical features of antiphospholipid syndrome test positive only for IgA, particularly in the context of systemic lupus erythematosus or catastrophic APS.
Inclusion of β2GPI IgA testing may identify patients who are 'seronegative' by classic criteria but who carry antiphospholipid antibody–mediated risk. Its independent predictive value remains debated, and it is not universally measured in all laboratories.
IgM antibodies to β2GPI occur transiently after infections or may appear alongside IgG in autoimmune contexts. IgM is larger and pentameric, leading to different complement-activating properties compared with IgG, and is more likely to be a false-positive or transient finding.
β2GPI IgM is less consistently associated with thrombotic events than IgG. Isolated IgM positivity, especially at low titre, often reflects a transient response and must be confirmed at 12 weeks before attributing clinical significance.
Why is the β2GPI Antibodies test ordered?
- Investigation of unexplained arterial or venous thrombosis, particularly in young patients or those with atypical sites (cerebral, mesenteric, portal)
- Work-up of recurrent early pregnancy loss (three or more consecutive miscarriages before 10 weeks' gestation) or late pregnancy morbidity (fetal death ≥10 weeks, severe pre-eclampsia, or placental insufficiency)
- Evaluation of thrombocytopenia or haemolytic anaemia in the context of suspected autoimmune disease or systemic lupus erythematosus
- Assessment of livedo reticularis, cutaneous necrosis, or unexplained neurological events (stroke, transient ischaemic attack) in younger adults
- Confirmatory testing after a positive lupus anticoagulant or anticardiolipin result, to complete the antiphospholipid antibody panel
- Screening before starting oestrogen-containing contraceptives or hormone replacement therapy in patients with a personal or family history of thrombophilia
- Prolonged activated partial thromboplastin time (aPTT) without bleeding, prompting evaluation for lupus anticoagulant and associated antibodies
- Pre-operative or pre-pregnancy thrombotic risk stratification in patients with a known autoimmune condition
Sample collection and turnaround
Sample type
Blood (plasma)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
3–5 business days
Collection notes
Phlebotomy via Quest at a patient service centre. Citrated plasma is typically used for this assay (check with the performing laboratory; some accept serum). Avoid haemolysed or lipemic specimens. If possible, draw before starting anticoagulation to avoid confounding lupus anticoagulant testing, though anticoagulation does not directly interfere with β2GPI antibody ELISA.
Specimen requirements
Minimum 1 mL citrated plasma (or serum, depending on laboratory protocol). Separate plasma from cells within two hours. Stable refrigerated for 24–48 hours; freeze if longer storage is required. Note the performing laboratory for serial comparability, as assays and units differ.
What can affect β2GPI Antibodies results?
Transient low-titre antiphospholipid antibodies (particularly IgM) can appear during or after viral or bacterial infections and typically resolve; confirmatory testing at 12 weeks distinguishes persistent from transient positivity.
Warfarin and direct oral anticoagulants do not directly interfere with ELISA for β2GPI antibodies, but they may affect concurrent lupus anticoagulant assays; collecting samples before anticoagulation is ideal when feasible.
High-dose corticosteroids, rituximab, or other immunosuppression can lower antibody titres, potentially causing false-negative results in treated patients.
Different platforms and reference standards (GPL, MPL, APL units versus standardised U/mL) yield results that are not interchangeable; serial monitoring should use the same laboratory and assay.
Haemolysed or lipemic specimens can interfere with ELISA optical density readings, leading to spurious results; grossly abnormal samples should be rejected and redrawn.
Pregnancy itself can modestly alter immune responses and antiphospholipid antibody levels, but persistent high-titre antibodies remain clinically significant; false-positive tests are uncommon in pregnancy.
What do β2GPI Antibodies results mean?
Elevated
High-titre β2GPI IgG (>40 U/mL, especially >80 U/mL) is strongly associated with thrombotic events and pregnancy morbidity, particularly when accompanied by lupus anticoagulant or high-titre anticardiolipin IgG. Isolated IgA or IgM positivity, especially at low titre, is less predictive and must be confirmed at ≥12 weeks. Indeterminate results (20–80 U/mL) require repeat testing and correlation with clinical features and other antiphospholipid antibodies before diagnosing APS.
Normal
Negative results (<20 U/mL across all isotypes) make antiphospholipid syndrome less likely but do not exclude it; lupus anticoagulant or anticardiolipin antibodies may be positive in isolation. Seronegative APS, in which clinical features are present without detectable antibodies, is recognised but rare.
Reduced
Not applicable — antibody levels are reported as negative, indeterminate, or positive rather than as a reduction from a baseline.
Note: β2GPI antibodies must be interpreted alongside lupus anticoagulant and anticardiolipin antibodies — the full triad determines APS classification. Transient low-titre positivity, particularly IgM, is common after infection and does not confer thrombotic risk; APS criteria require persistence at ≥12 weeks. Assay variability means that cut-offs and units differ between laboratories, so serial results should be compared within the same platform.
Frequently asked questions
β2GPI antibodies, particularly high-titre IgG, are one of three laboratory criteria for APS alongside lupus anticoagulant and anticardiolipin antibodies. They bind β2GPI when it is complexed with phospholipids, triggering endothelial activation and dysregulated coagulation, leading to thrombosis and pregnancy complications.
How to access the β2GPI Antibodies test
The β2GPI Antibodies reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. (2006)
- Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. (2018)
- Pengo V, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. (2010)
- Andreoli L, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. (2017)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.